Table 4.
Region-based positivity rate of PSMA-11 PET/CT and metastatic extent according to patients’ characteristics before PSMA-11 PET/CT
| Nb PET/CT examinations | PSMA-11 positive with pelvic foci only | PSMA-11 positive with distant foci | Foci in prostate fossa | Foci in pelvic lymph nodes | Foci in extra-pelvic lymph nodes | Foci in the skeleton | Foci in visceral organs | 1–3 metastatic foci | 4–5 metastatic foci | ≥ 6 metastatic foci | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall | 1084 | 34% | 35% | 26% | 34% | 20% | 15% | 4% | 31% | 6% | 15% |
| Gleason score (n = 1007) | |||||||||||
| < 7 | 166 | 40% | 23% | 36% | 23% | 13% | 9% | 1% | 20% | 4% | 11% |
| = 7 | 660 | 33% | 35% | 23% | 36% | 21% | 17% | 4% | 33% | 6% | 15% |
| > 7 | 181 | 33% | 40% | 29% | 35% | 23% | 18% | 6% | 36% | 6% | 15% |
| Initial therapy | |||||||||||
| Prostatectomy (PX) | 877 | 29% | 35% | 18% | 34% | 20% | 15% | 4% | 33% | 6% | 13% |
| Other curative modality | 207 | 53% | 32% | 58% | 33% | 20% | 16% | 4% | 23% | 4% | 20% |
| Previous recurrence | |||||||||||
| No (1st recurrence) | 433 | 41% | 21% | 33% | 30% | 11% | 10% | 2% | 27% | 3% | 11% |
| Yes | 651 | 29% | 43% | 21% | 37% | 26% | 19% | 5% | 34% | 8% | 17% |
| Serum PSA for PSMA-11 PET/CT (ng/mL) | |||||||||||
| < 0.2 | 17 | 41% | 0% | 18% | 24% | 0% | 0% | 0% | 24% | 0% | 0% |
| ≥ 0.2 < 0.5 | 166 | 28% | 14% | 12% | 25% | 6% | 8% | 1% | 30% | 1% | 2% |
| ≥ 0.5 < 1 | 173 | 34% | 29% | 29% | 31% | 14% | 16% | 3% | 37% | 7% | 5% |
| ≥ 1 < 2 | 257 | 35% | 32% | 23% | 33% | 16% | 18% | 2% | 34% | 7% | 10% |
| ≥ 2 | 471 | 35% | 46% | 36% | 41% | 30% | 20% | 7% | 30% | 6% | 27% |
| FCH PET/CT | |||||||||||
| Negative | 924 | 32% | 34% | 24% | 33% | 21% | 15% | 4% | 30% | 6% | 14% |
| Equivocal | 160 | 45% | 37% | 36% | 43% | 18% | 18% | 7% | 38% | 3% | 19% |